A new weight control treatment was recently approved in Mexico. This is Tirzepatida, the compound previously It was used in patients with type 2 diabetesAnd this can now be used as k Obesity.
His arrival in pharmacies It is scheduled to be held in June 2025Also, the Laila Pharmaceutical Company, the manufacturer of products.
The decision to expand its use depends on the results of the Surmount-5 clinical study, whose data were presented during the European Conference on obesity (ECO 2025).
In this article, adults are obese or overweight Receive Tirzepatida or Semaglutida as an active comparison. All participants They also received food support and the recommendations of physical activity.
You may be interested in reading: These are the risk of taking OzemPIC or semaglutida without medical treatment
According to the study, patients treated with Pullzepatida They lost, on average, 20.2 % of body weight in a period of 72 weeksCompared to 13.7 % of those who received Smaglutida.
This difference of 6.5 degrees Celsius is an additional loss of about 7.8 kg per person.
In addition, 64.6 % of the participants who used Tirzepatida managed to reduce at least 15 % of their initial weight, compared to 40.1 % in the semaglutida group.
Public health context
Obesity is a chronic disease that affects millions of people in Mexico. According to official data, about 70 % of the adult population It provides a degree of weight gain or obesity.
This is linked to an increase in the risk of growth Cardiovascular disease, type 2 diabetes and high blood pressureAmong the other accompanying diseases.
In the study, adults were included with obesity or weight gain, but without diabetes diagnosis. They should also provide at least a common in excess weight, such as sleeping, high blood pressure, or red bloodstream.
What is tirzepatida?
Tirzepatida It is a dual riot of GIP and LPG-1 receptorsTwo hormones that Organizing the metabolism of appetite, satiety and glucose.
His joint work has been investigated in various clinical trials to assess its effectiveness in reducing weight and controlling metabolism.
The Surmount-5 Double Divide and Phase 3B study, and compared Tirzepatida (at a dose of 15 mg) with semaglutida (2.4 mg), which is currently approved in Mexico as a treatment for obesity.
Marketing and monitoring Tirzepatida
The license to use obesity includes its distribution under the prescription. Medicine It will be available in Mexico from June 2025According to the information provided by the company.
It is expected that in the coming months, training for medical workers will be implemented Learn the clinical file for the drug Medical prescription standards.
Currently, Tirzepatida was patent as a therapeutic option to manage body weight in adults with obesity or weight gain, but its use should be evaluated according to the case, under medical supervision.
BGPA
(Tirzepatid)
Story Credit